Both preservative-free, contact lens-friendly drops will be available in most national retailers.

IVMED-85 is a preservative-free, nonatropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

This strategic investment will allow both companies to better serve the Canadian market.

Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.

Diane Russo, OD, MPH, MBA, FAAO, Dipl AAO PH, and Nicole Quinn, OD, FAAO, highlight the continued importance of residencies in optometric practices.

The PDUFA date for Brimochol PF is January 28, 2026.

Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.

Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.

At the Collaborative Care Symposium, Rachelle Lin, OD, MS, FAAO, highlighted how newer retinal therapies are addressing treatment gaps by offering extended dosing intervals without compromising efficacy—ultimately easing the burden on both patients and providers.

Increases in the doses of atropine were most common following the pandemic and especially among patients for whom therapy was initiated with the 0.01% dose.

The qVPT, a suprathreshold test comprised of 15 trials at 9 cycles per degree and 20% contrast, measures the patient’s response time to visual stimuli and the number of correct responses.

A recent US Court of International Trade decision was made on May 28 to permanently prohibit all tariffs imposed by President Donald J. Trump under the International Emergency Economic Powers Act.

Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.

Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.

Catch up on the top stories in optometry during the week of May 26-May 30.

Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1310 nm that can scan at a speed of 50,000 A-scan/second.

The partnership aims to accelerate Pangaea’s efforts to address critical care gaps in eye health and systemic disease.

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.